Korsana Biosciences, Inc. — Form SCHEDULE 13D
Filed September 11, 2026 · analyzed by the Ownership Agent
SCHEDULE 13D
— Neutral
significance 45/100
What the filing says
Fairmount Funds Management LLC filed a Schedule 13D on September 11, 2026, indicating acquisition of beneficial ownership in Korsana Biosciences. The filing does not disclose specific share count, percentage ownership, or dollar amount in the provided text excerpts. Without concrete ownership figures, the materiality of this stake relative to Korsana's ~$5.7M market cap cannot be determined from available information.
Why this rating
Schedule 13D signals meaningful stake (typically >5%), but specifics absent. At $5.7M market cap, even modest ownership is material; filing triggers disclosure but direction/magnitude unclear.
See more from September 11, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.